Anti-tau antibodies include semorinemab, and ABBV-8E12, also known as tilavonemab, and these antibodies have been recently reported to have no efficacy in AD (Teng et al, 2022; Florian et al, 2023). This evidence concerns the gene MAPT and Alzheimer disease.